Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $20.3 million.

  • Kiniksa Pharmaceuticals International's Cost of Revenue rose 73.6% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.6 million, marking a year-over-year increase of 4187.61%. This contributed to the annual value of $60.9 million for FY2024, which is 8232.71% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Cost of Revenue stood at $20.3 million, which was up 73.6% from $18.6 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Cost of Revenue registered a high of $20.3 million during Q3 2025, and its lowest value of $491000.0 during Q1 2023.
  • Its 5-year average for Cost of Revenue is $9.8 million, with a median of $8.4 million in 2023.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Cost of Revenue tumbled by 8836.22% in 2023 and then soared by 205539.71% in 2024.
  • Kiniksa Pharmaceuticals International's Cost of Revenue (Quarter) stood at $3.9 million in 2021, then skyrocketed by 73.52% to $6.7 million in 2022, then soared by 42.83% to $9.6 million in 2023, then surged by 86.73% to $17.9 million in 2024, then grew by 13.19% to $20.3 million in 2025.
  • Its Cost of Revenue stands at $20.3 million for Q3 2025, versus $18.6 million for Q2 2025 and $17.9 million for Q1 2025.